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Aims: To investigate the long-term safety of inhaled iloprost in patients with pulmonary hyper-
tension (pH), including idiopathic PAH (IPAH group) and other forms of pulmonary hypertension
(PHother).
Methods and results: Sixty-three patients (IPAH group, nZ 40, PHother nZ 23) were enrolled
to receive inhaled iloprost either from baseline or after 3 months in a prospective, open-label
2-year study. Iloprost was inhaled 6e9 times daily with a night pause employing a jet nebulizer
delivering an inhaled single dose of 4 mg at the mouthpiece. In the case of side effects the
single dose was reduced to 2 mg. Sixty patients received at least 1 dose of inhaled iloprost.onsored by Schering AG, Berlin, Germany; ClinicalTrials.gov Identifier: NCT00414687.
ulmonology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 20, A-8036
; fax: þ43 316 385 3578.
medunigraz.at (H. Olschewski).
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732 H. Olschewski et al.Thirty-six patients completed at least 630 days of therapy (25 IPAH, 11 PHother), 19 patients
dropped out prematurely and 8 patients died (3 IPAH, 5 PHother). There were no drug-induced
toxicities and only mild to moderate side effects. The most common side effects were cough-
ing and flushing. Two-year survival was estimated at 85% (IPAH group 91%, PHother 78%). A
modified analysis was performed to correct for differential drop-out. It included follow-up
data from the premature discontinuations and revealed a 2-year survival of 87% [95% CI,
76%e98%] in the IPAH group while the predicted survival was 63%. The iloprost dose increased
by 16% over 2 years.
Conclusion: Inhaled iloprost is well tolerated as long-term therapy and no substantial dose
increase is required. Although uncontrolled, the data suggest a long-term clinical benefit from
continued therapy with inhaled iloprost.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Although pulmonary arterial hypertension (PAH) has
become a treatable disease, therapeutic outcome is still
not ideal and there is need for further development.
Prostanoids (prostacyclin analogs) such as epoprostenol and
the stable analogs iloprost, beraprost, and treprostinil have
been tested in randomized controlled trials.1e4 The same is
true for the endothelin receptor antagonists bosentan,5
sitaxsentan,6 ambrisentan,7 and the phosphodiesterase
inhibitors sildenafil8 and tadalafil.9 Documented long-term
experience in a significant number of patients suggests
a survival benefit for continuous intravenous epoproste-
nol.10e12 Epoprostenol has several risks including catheter
complications, rebound pulmonary hypertensive crisis, and
systemic side effects.
Inhaled iloprost combines the antiaggregatory, anti-
proliferative, and vasodilatory properties of prostanoids
with pulmonary and intrapulmonary selectivity avoiding
systemic pressure drop and ventilation/perfusion mis-
match.13e17 The clinical efficacy of this approach has been
demonstrated in a randomized placebo-controlled study.4
Inhaled iloprost added to long-term bosentan therapy and
has been shown to have a favorable safety and efficacy
profile in patients with pulmonary arterial hypertension.18
The present study aimed to evaluate the long-term
safety of inhaled iloprost in patients with different forms of
pulmonary hypertension, as well as assessing its effect on
survival and clinical parameters. The results suggest that
inhaled iloprost is well tolerated on a long-term basis and
has sustained efficacy over 2 years in the majority of
patients, even when administered at a constant dose.
Patients and methods
The study started independently of and prior to the AIR
study,4 and its aims were evaluation of long-term safety
and efficacy and hypothesis generation. None of the
patients of this study was enrolled in the AIR study or vice
versa. The enrolment period was one year. Patients eligible
for study participation had either idiopathic or familial
PAH, previously classified as primary pulmonary hyperten-
sion (IPAH group), or other forms of pH, previously classified
as secondary pulmonary hypertension (PHother). Patients
ranged in age from 18 to 70 years and had a meanpulmonary arterial pressure (mPAP) at rest of 40 mm Hg.
This high threshold was chosen to select for patients who
suffered from severe pulmonary vasculopathy as their main
exercise and prognosis limiting factor. Patients were
excluded from participation if they showed one or more
prospectively defined signs of clinical instability (6-minute
walk distance (6-MWD)< 50 m, cardiac index< 1.5 L/min/
m2 or central venous pressure> 20 mmHg despite adequate
diuretic therapy, advanced renal or hepatic failure). Other
general exclusion criteria were significant systolic or dia-
stolic left ventricular failure (PAWP> 12 mmHg), life-
threatening ventricular arrhythmias, uncontrolled systemic
arterial hypertension, global respiratory insufficiency
(PCO2> 44mmHg), severe cerebrovascular disease, coa-
gulopathy or recent history of gastrointestinal bleeding
within the last 6 months, active cancer, HIV infection, and
substance abuse as well as acute thromboembolism within
the previous 12 months, and pulmonary veno-occlusive
disease. In addition, for the IPAH group, chronic thrombo-
embolism, significant lung disease, and any associated
disease like scleroderma were excluded. NYHA class was
not used as inclusion or exclusion criteria. Baseline medi-
cations were allowed except for prostanoids, endothelin
receptor antagonists, beta blockers, and phosphodiesterase
inhibitors. Calcium channel blockers which were in place
for at least 6 weeks prior to baseline, independent of the
original indication, were continued on a stable dose
throughout the study. All patients gave their written
informed consent prior to participation. The study was
approved by independent ethics committees for all 10
participating expert centers in Germany and conducted in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
Patients were randomized to receive inhaled iloprost
either immediately after completion of baseline evalua-
tions, or 3 months later to provide a control group for
assessment of safety during the first 3 months. Iloprost
treatment was administered in this study for up to 2 years
(Fig. 1). Inhaled iloprost was given on top of common
background therapy including oxygen and all medications.
Control patients who developed any of the defined signs of
clinical instability could prematurely switch to inhaled ilo-
prost treatment and remain in the study. Not all these
patients were labeled with ‘‘clinical instability’’ as the
main reason for premature discontinuation of the control
period in their case record forms (CRF). Independently,
Assessed for eligibility (n=79) 
    Randomized (n=63)   
Allocated to receive inhaled iloprost plus standard Allocated to receive standard 
therapy (n=30)  standard therapy alone (n=33)      
          -  Death, 1*
Began the allocated treatment (n=29)  Began the allocated treatment 
(n=33)
Prematurely discontinued (n=7)    Prematurely discontinued (n=7)&
- Death, 1      - Death, 1†
- Lack of efficacy, 1      - Adverse event, 3‡
- Protocol deviation, 1     - Other, 3 (clinical instability 1,
- Withdrawal of consent, 4 right heart failure 1, lung        
transplant 1#)     
Completed randomized phase (n=22)       Completed randomized phase (n=26) 
Entered long-term phase (n=22)    Entered long-term phase (n=30) §
Prematurely discontinued (n=6)    Prematurely discontinued (n=10) 
- Lack of efficacy, 3     - Lack of efficacy, 3¶
- Consent withdrawn, 1    - Death, 2 
- Other, 2      - Adverse event, 2 
        (both lung transplant)    - Consent withdrawn, 2 
                   - Other, 1 (noncompliance) 
Completed long-term phase (n=16)  Completed long-term phase (n=20) 
Figure 1 Disposition of study patients. This flow chart gives the reasons for premature discontinuation of the study according to
the original CRF entries. Five patients discontinued due to death and another 3 patients discontinued for another reason and died
within 4 weeks after discontinuation (per protocol nZ 8 deaths). *One patient in the iloprost group died prior to beginning the
allocated intervention. &Five patients met the criteria of clinical instability and were prematurely started on inhaled iloprost. yThis
patient received inhaled iloprost after showing signs of clinical instability, but died after 4 days and did not enter the long-term
phase. zOne patient who never received iloprost discontinued due to an adverse event and died within 4 weeks of leaving the study.
#One patient received a donor lung and was transplanted without prior iloprost inhalation. xFour patients with clinical instability
entered the long-term phase. {Two patients who discontinued due to lack of efficacy in the long-term phase died within 4 weeks of
leaving the study.
Long-term inhaled iloprost for PH 733patients were permitted to leave the study for any reason
at any time and e.g. switch to the best alternative therapy,
including intravenous prostanoids.
The initial daily dose of iloprost (measured at the
mouthpiece of the inhalation device) was 6 times daily
4 mg, inhaled during daytime with an overnight break. Each
inhalation took about 10 min. Iloprost was delivered using
a valve-operated inhalation set (Ilo-Neb, manufactured by
Nebu-Tec, Elsenfeld, Germany). Alterations of the inhaled
iloprost dose (to a minimum of 12 mg/day) or frequency (to
a maximum of 9 times daily, or 36 mg/day) were permitted
according to individual tolerance after the first 3 days of
therapy. Treatment compliance was recorded by the
investigator at each study visit including the patient’s notes
and the drug supplies (unused, partly used, and empty
ampoules were to be returned to the investigator at the
scheduled visit).Patient assessment
Safety and tolerability were evaluated by serial monitoring
of adverse events, vital signs, and laboratory tests. For
assessment of clinical effects, patients underwent baseline
evaluation comprising a physical examination, routine
laboratory tests, and recording of the medical history,
a non-encouraged 6-minute walk distance test (6-MWD),19
and right heart catheterization to measure acute hemody-
namic parameters before and after inhalation of iloprost.
Further baseline assessment included the modified New
York Heart Association functional classification (NYHA
class), the Borg dyspnea scale (ranging from 6 to 20 with
higher scores reflecting worse dyspnea) 20 and assessment
of quality of life using the EuroQol visual analog scale (EQ-
VAS) 21 and the Mahler dyspnea score.22 The EQ-VAS is
a self-rated visual analog scale that is 20 cm long and
Table 1 Baseline characteristics of intent-to-treat population.
Iloprost group Control group All patients
Number of patients 30 33 63
Agea (yr) 42.0 2.2 48.8 2.1 45.5 1.5
Weighta (kg) 69.2 2.7 70.2 2.4 69.7 1.8
Sexb
Male 7 (23.3) 12 (36.4) 19 (30.2)
Female 23 (76.7) 21 (63.6) 44 (69.8)
Underlying disease groupb
PPH group 20 (66.7) 20 (60.6) 40 (63.5)
PHother group 10 (33.3) 13 (39.4) 23 (36.5)
Use of calcium channel antagonistsb 12 (40.0) 18 (54.5) 30 (47.6)
6-Minute walk distancea (m) 353 23.5 330 22.9 341 16.3
NYHA functional class
II 11 (36.7) 10 (30.3) 21 (33.3)
III 13 (43.3) 17 (51.5) 30 (47.6)
IV 6 (20.0) 6 (18.2) 12 (19.0)
The IPAH group consisted of patients with idiopathic pulmonary arterial hypertension, the PHother group of patients with associated
PAH, chronic lung disease or chronic thromboembolic disease.
a Mean standard deviation.
b Number (percentage).
734 H. Olschewski et al.ranges from 0 to 100 (higher scores reflect a better quality
of life). The 3 components of the Mahler dyspnea score
(i.e., functional impairment, magnitude of task, and
magnitude of effort) were summed to yield the Mahler focal
score, which ranges from 0 to 12 (lower scores reflect
greater dyspnea). The Mahler transition index captures the
change from baseline in each of these 3 components (i.e.,
from 3 to þ3), and thus ranges from 9 to þ9 (positive
scores reflect improvement and negative scores reflect
worsened dyspnea).
The 6-MWD, NYHA classification, and quality of life
assessment were repeated regularly up to 24 months.
Further measurements performed at these intervals
included lung function tests, blood gas analysis, carbon
monoxide diffusing capacity, chest X-ray, and electrocar-
diography. Right heart catheterization was repeated at 3
months and at 1 and 2 years. A schedule of assessments is
provided in Table 1 in Supplementary data.
Statistical analysis
This phase 2 explorative study sought to enroll a total of 60
patients. It was not powered for group comparisons.
Continuous data are given as mean values standard
deviation (SD) or standard error (SE); categorical variables
are presented as frequencies and percentages. Assessment
of the clinical effect at the end of the study included all
patients who had an end-of-study evaluation at least 630
days post-baseline. Changes in 6-MWD from baseline to the
end of study (year 2) were assessed using the Hodgese
Lehmann estimate, including 95% confidence intervals (CI).
Missing data were not imputed.
Per protocol, all patients were followed until 2 years
after start of therapy or until 4 weeks after premature
study discontinuation; in addition, a modified analysis was
performed in which information on survival and trans-
plantation over 2 years from enrolment was collected forall patients who discontinued the study prematurely, using
a follow-up questionnaire. Survival was calculated by
intention-to-treat using KaplaneMeier methodology; the
95% CI is given for each time-to-event estimate. Addition-
ally, a combined outcome measure of event-free survival,
defined as absence of death, lung transplantation, or need
for alternative pH therapy, was calculated using Kaplane
Meier methods.
Results
Study population
A total of 63 patients were included in the study (intent-to-
treat (ITT) population). Inhaled iloprost treatment was
allocated to 30 patients from baseline onwards. Thirty-
three patients (control patients) were randomized to
receive iloprost 3 months after baseline (Fig. 1). Baseline
characteristics (Tables 1 and 2) were similar in these two
groups.
Patients with PHother included those with connective
tissue disease (nZ 5), cardiac shunt (nZ 4), interstitial
lung disease (nZ 5), chronic thromboembolic pulmonary
hypertension (nZ 5), liver cirrhosis (portopulmonary
hypertension) (nZ 3), and prior use of appetite suppres-
sants (nZ 1).
Treatment
Of the 30 patients randomized to receive inhaled iloprost
from baseline onwards, 29 patients began the treatment
and one patient died due to right heart failure prior to the
first inhalation. During the first 3 months, 7 patients on
iloprost and 7 control patients discontinued the study
prematurely (Fig. 1). One of the control patients
Table 2 Clinical effects of iloprost plus background therapy vs. iloprost alone.
Baseline End of studya (year 2)
Iloprost Control Iloprost Control
6-MWD
No. of patients tested 30 33 14 17
Absolute value (m)b,c 353 129 330 132 480 91 461 107
Mean change from baseline (m) 85.2 90.5
Borg dyspnea scale
No. of patients tested 30 33 16 19
Absolute valueb,c,d 15.1 2.3 14.5 2.5 13.8 2.3 13.6 2.2
Mean change from baseline 1.2 2.4 0.1 2.7
NYHA functional class
No. of patients tested 30 33 16 19
Patients (%)
Improved e e 7 (43.8) 5 (26.3)
Unchanged 5 (31.3) 13 (68.4)
Deteriorated 4 (25.0) 1 (5.3)
Mahler Dyspnea Score
No. of patients tested 30 33 16 19
Absolute valueb,e 4.8 2.1 4.8 1.6 5.8 2.0 5.8 1.8
EuroQol visual analog scale (EQ-VAS)
No. of patients tested 25 30 16 18
Absolute value (mm)b,f 48.8 22.8 41.3 20.2 66.9 15.5 54.9 26.0
Mean change from baseline (mm) 19.4 15.6 9.3 23.2
6-MWD, 6-minute walk distance.
a Values are those from all patients having an end-of-study visit at least 630 days post-baseline.
b Mean standard deviation.
c Values are pre-inhalation (i.e. trough).
d Range is from 6 to 20, with higher scores reflecting worse dyspnea at the end of the 6 minute walk test.
e Baseline values reflect the focal score (range from 0 (worst condition) to 12 (best condition)); changes from baseline reflect the
transition score (range, 9 (least favorable change) to þ9 (most favorable change)).
f The visual analogue scale ranges from 0 to 100 with higher scores reflecting a better quality of life.
Long-term inhaled iloprost for PH 735discontinued the study due to an ‘‘adverse event’’ and died
before any alternative treatment was started. Five of the
control patients (all PHother) who met the predefined
criteria for clinical instability were prematurely treated
with inhaled iloprost. Only in one of these patients ‘‘clinical
instability’’ was given as the main reason for premature
discontinuation of the control period (Table 1). In the other
patients ‘‘adverse event’’ (nZ 2), ‘‘right heart failure’’
(nZ 1), and ‘‘death’’ (nZ 1) was entered into the CRF.
Indeed, the last patient died four days after start of iloprost
therapy. This patient did not reach the long-term period. A
second patient discontinued inhaled iloprost after 3 weeks
due to ‘‘lack of efficacy’’ and died 2 months later. The
remaining 3 patients were stabilized clinically and
completed the 2-year study. The criteria for clinical insta-
bility were not met by any of the patients in the iloprost
group. Patients in the iloprost group who began treatment
discontinued due to death from pneumonia (nZ 1), with-
drawal of consent (nZ 4), lack of efficacy (nZ 1) and
protocol deviation (nZ 1).
Fifty-two patients entered the long-term phase of the
study. Of these patients, 36 (69%) completed 2 years of
iloprost therapy. Sixteen patients discontinued the long-
term study prematurely due to death (nZ 2), lack ofefficacy (nZ 6), adverse events (nZ 2), and other reasons
(nZ 6), including withdrawal of consent and lung trans-
plantation. Two patients (1 IPAH group, 1 PHother) who
discontinued due to lack of efficacy, died within 4 weeks
after premature discontinuation. One patient with idio-
pathic PAH received additional therapy with intravenous
iloprost and remained in the study. A follow-up question-
naire was used to obtain information on all patients who
discontinued prematurely.
The mean inhaled daily dose of iloprost divided into 6e9
doses was 25 mg at month 1 and 29 mg at year 2. The mean
dose increase was 16% over the course of the 2-year study.
A total of 60 patients received at least one iloprost inha-
lation during the study. Two patients self-administered
iloprost at night, either regularly or occasionally.Adverse events
The majority of patients (79%) experienced an adverse
event in the randomized phase of the study (Table 3), and
nearly all patients (95%) experienced an adverse event over
the 2-year study period (Table 4). The most frequent
adverse events in the randomized phase were increased
Table 3 Adverse events in patients treated with inhaled
iloprost or placebo during the randomized phase (first 3
months) of the study.
Adverse event n (%) Iloprost 3
months
nZ 30
Control 3
months
nZ 33
All patients
3 months
nZ 63
At least one
adverse event
25 (83) 25 (76) 50 (79)
Increased cough 8 (27) 6 (18) 14 (22)
Vasodilatation 8 (27) 4 (12) 12 (19)
Peripheral edema 3 (10) 6 (18) 9 (14)
Chest pain 4 (13) 3 (9) 7 (11)
Headache 4 (13) 3 (9) 7 (11)
Right heart failure 3 (10) 4 (12) 7 (11)
Values are given as numbers of patients (%).
736 H. Olschewski et al.cough, vasodilatation (flushing) and peripheral edema
(Table 3). Over the course of the 2-year study, headache
and infection were also among the most commonly repor-
ted adverse events (Table 4).
A total of 5 patients discontinued due to an adverse
event over the 2-year study period. Three of these
patients, however, discontinued during the first 3 months
when they did not receive inhaled iloprost. The other 2Table 4 Adverse events during the 2-year study period (random
Adverse event n (%) Formerly randomized
to iloprost 2 years nZ 30
At least one adverse event 28 (93)
Increased cough 13 (43)
Headache 8 (27)
Infection 11 (37)
Peripheral edema 7 (23)
Vasodilatation 12 (40)
Dizziness 7 (23)
Nausea 9 (30)
Right heart failure 5 (17)
Chest pain 7 (23)
Edema 7 (23)
Bronchitis 7 (23)
Back pain 5 (17)
Asthenia 4 (13)
Upper respiratory infection 5 (17)
Flu syndrome 5 (17)
Death 2 (7)
Diarrhea 4 (13)
Palpitation 3 (10)
Syncope 5 (17)
Dyspnea 4 (13)
Epistaxis 3 (10)
Surgery 3 (10)
Throat pain 5 (17)
Trismus 4 (13)
Vertigo 3 (30)
Values are given as numbers of patients (%). Adverse events from the
iloprost and former control patients were pooled.patients discontinued for adverse events while actually
receiving iloprost: one patient discontinued after 4 weeks
of therapy due to back pain, headache, and vertigo after
each inhalation, and the other patient discontinued after 6
months of therapy due to local irritation to the pharynx
upon inhalation following radiation therapy for squamous
cell carcinoma.
Serious adverse events
During the first 3 months, the frequency of serious adverse
events was similar in the iloprost-treated (23%) and control
patients (21%). The overall frequency of serious adverse
events was 57% during the 2-year study period; the most
frequent event was right heart failure (24%), followed by
death and surgery.
Survival
According to the per protocol analysis, 4 patients died
during the first 3 months of the study (2 patients
died before the first iloprost inhalation), and 4 patients
died between month 3 and 24. The estimated 2-year
survival rates were 91.4% (95% CI, 81e100%) in patients with
IPAH and 61.9% (95% CI, 41e83%) among patients in the
PHother group.ized phase and open-label extension).
Formerly randomized
to placebo 2 years nZ 33
All patients
2 years nZ 63
32 (97) 60 (95)
11 (33) 24 (38)
15 (46) 23 (37)
10 (30) 21 (33)
12 (36) 19 (30)
7 (21) 19 (30)
9 (27) 16 (25)
7 (21) 16 (25)
10 (30) 15 (24)
8 (24) 15 (24)
6 (18) 13 (21)
6 (18) 13 (21)
7 (21) 12 (19)
7 (21) 11 (18)
6 (18) 11 (18)
4 (12) 9 (14)
6 (18) 8 (13)
4 (12) 8 (13)
5 (15) 8 (13)
3 (9) 8 (13)
3 (9) 7 (11)
4 (12) 7 (11)
4 (12) 7 (11)
2 (6) 7 (11)
3 (9) 7 (11)
4 (12) 7 (11)
randomized phase and the long-term treatment phase in former
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Figure 2 KaplaneMeier estimates of survival of patients with IPAH. Diamonds represent the IPAH patients (nZ 39). Predicted
survival according to D’Alonzo et al.23 Open circles indicate patients who prematurely or regularly (after 2 years) discontinued the
study.
Long-term inhaled iloprost for PH 737The modified analysis was based on those 60 patients
who had received at least one dose of inhaled iloprost.
Including the additional information on survival, trans-
plantation, and medication for those 18 patients who
prematurely discontinued the study, the actual 2-year
survival rate was 78% for all patients (nZ 60; 95% CI,
67e89%), 87% for the IPAH patients (nZ 39; 95% CI, 76e
98%) and 62% (nZ 21; 95% CI, 41e83%) for the other
patients. Interestingly, 12 of these 18 patients did not
receive any disease-targeted therapy after premature
study discontinuation. The 2-year event-free survival was
calculated at 74% (95% CI, 60e88%) in the IPAH patients and
52% (95%CI, 31e74%) in the other patients. According to the
D’Alonzo formula,23 the predicted survival rate for the
patients in the IPAH group was 63% (Fig. 2).
Clinical effects
In the 31 patients with 6-MWD evaluation after 2 years, 6-
MWD improved from baseline by 89 m (95% CI: 51ee125 m,
HodgeseLehmann estimate for the paired difference), or
34%. The Borg dyspnea scale showed stabilization. During
long-term iloprost treatment, NYHA class improved from
baseline in nZ 12 (34%) study patients (Table 2). Measure-
ment of hemodynamic parameters supported a maintainedTable 5 Hemodynamic parameters.a
Baseline End of
Iloprost Control Pre-in
Chang
mPAP, mmHg (n) 57.2 15.1 (30) 54.1 13.0 (33) 2.2
PVR, dyn s/cm5 (n) 1094 468 (26) 1065 403 (32) 126
CO, L/min (n) 3.9 1.2 (30) 3.8 1.2 (33) 0.1
SvO2, % (n) 62.8 7.5 (29) 62.7 10.2 (33) 0.1
PAPZ pulmonary artery pressure; PVRZ pulmonary vascular resistanc
a Mean and standard deviation are given with number of patients teresponsiveness to inhaled iloprost at 2 years: there was
a significant reduction in peak mean pulmonary arterial
pressure and pulmonary vascular resistance compared with
baseline and a stabilization or increase in cardiac output and
mixed venous oxygen saturation (Table 5). There was also
a trend for improvement in trough values. The mean Mahler
transition index and the EuroQol visual analog scale were
still consistently improved after 2 years (Table 2).
Discussion
This study prospectively evaluated the long-term safety of
inhaled iloprost in patients with pulmonary hypertension. It
showed excellent tolerance of inhaled iloprost over the 2-
year study period in the intent-to-treat population (ITT)
population and considerable improvement in those patients
who remained on iloprost treatment for 2 years.
The adverse event profile of iloprost in the randomized
phase was similar to the AIR study4 and showed a tendency
to increased coughing and flushing in the iloprost group. In
the long run there was no major change in the adverse
event profile. Coughing and typical prostanoid side effects
like vasodilation and headache were among the most
common adverse events but also infection was relatively
common. Infection rates have not been reported from otherstudy (year 2): all patients
halation (trough) Post-inhalation (peak)
e from baseline p-value Change from baseline p-value
12.8 (33) 0.436 11.2 14.4 (33) 0.000
 394 (28) 0.148 389 353 (28) 0.000
 1.2 (33) 0.681 0.6 1.2 (33) 0.017
 9.6 (29) 0.851 3.1 10.3 (30) 0.151
e; COZ cardiac output; SvO2Zmixed venous oxygen saturation.
sted in brackets.
738 H. Olschewski et al.long-term observations with PAH drugs except for clinically
significant line infections with intravenous epoprostenol
therapy. The incidence was between 0.1/yr24 in very
experienced PAH centers and up to 3/yr in other patient
populations. Compared to this, the total infection rate in
our study (0.16/yr) did not appear excessively high.
As a limitation of our study, 43% (27/63) of the ITT
population did not receive inhaled iloprost for the duration
of the whole 2-year study period; nevertheless, all ITT
patients were followed up by questionnaire. The reasons
for premature discontinuation of inhaled iloprost therapy
included lack of efficacy (nZ 7, 11%), withdrawal of
consent (nZ 7, 11%) and death (nZ 5, 8%). Two of the
deaths occurred in critically ill patients who died before
the first dose of iloprost was applied. Although adverse
events occurred in the majority of patients, this was the
reason for premature discontinuation in only 3 patients,
one of whom did not receive iloprost at any time. There
were 3 additional patients who dropped out due to lung
transplantation and 2 dropped out due to protocol devia-
tions or noncompliance.
The total number of premature drop-outs may appear
large but it must be considered that only one of the
patients in the study received a combination therapy
(intravenous iloprost on top of inhaled iloprost) while most
patients who were to be given an intravenous prostanoid
prematurely dropped out of the study (termed as ‘‘adverse
event’’, ‘‘lack of efficacy’’ or ‘‘withdrawal of consent’’). In
comparison, in the long-term extension studies with
bosentan, 30e44% of the study population received intra-
venous medication as add-on therapy and remained in the
study.25,26 In the long-term extension study with subcuta-
neous treprostinil, only 36% of the ITT population remained
on the study medication after 2 years.27
Other limitations of the study should be acknowledged.
The open-label nature of the trial might tend to bias
patient or physician preferences and thus affect outcomes.
This may have affected the assessment of clinical insta-
bility which led to early initiation of inhaled iloprost
treatment in patients who were randomized to the control
group. A further limitation is the small sample size and the
heterogeneity of the study population. However, inclusion
of PAH and other forms of pH in the study population may
have provided valuable new information regarding the long-
term use of iloprost.
If those patients are considered who remained on study
medication, results at completion of the open-label 2-year
study period demonstrate clinical improvement or stabili-
zation in all parameters, as evidenced by an increase inmean
6-MWD from baseline by 89 m, improvement or stabilization
in NYHA class in 86% of evaluated patients, and improve-
ments from baseline in self-assessed scales reflecting quality
of life (i.e. EQ-VAS, Borg dyspnea score, Mahler transition
dyspnea index). Both post-inhalational (i.e. peak drug
effect) and pre-inhalational (i.e. trough drug effect) hemo-
dynamics were stabilized or significantly improved.
However, these results are limited in that measurements
wereavailable in only a subsetof theentire studypopulation.
In the randomized phase there were only minor and mostly
non-significant differences in favour of iloprost in the effi-
cacy parameters. As the study was not powered for efficacy
we will not discuss this in further detail.It is of interest that the mean increase in the inhaled
iloprost dose was only 16% from week 1 over the 2-year
period, suggesting that development of tolerance to
inhaled iloprost (with resultant need for higher doses) is
uncommon. This may be due to the intermittent nature of
inhaled iloprost dosing or by the means of application. With
continuous infusion of epoprostenol1 or treprostinil,28
a several-fold dose increase is required to maintain benefit,
particularly in the first 3 months of therapy, suggesting the
development of tolerance. Similar experiences have been
reported for continuous iloprost infusion although there are
only few published data.29,30
The estimated survival of patients with IPAH over the 2-
year study period was 91% (95% CI, 81% to 100%). Using the
most conservative approach, i.e. including all those
patients who received at least one iloprost inhalation over
the two years even if they did not receive any targeted
therapy for most of the 2 years, survival in patients with
IPAH was 87% (95% CI, 76e98%). Although comparisons with
predictions based on historical data must be interpreted
with caution, the reduction of the 2-year mortality from
37% (predicted according to the D’Alonzo formula) to 13%
appeared substantial. These results suggest that inhaled
iloprost therapy might improve survival. In a long-term
study of continuous intravenous epoprostenol therapy by
Barst et al.,10 the 2-year survival rate was 72.4% (as
compared to the 51.6% survival rate in historical controls),
and a study by Sitbon et al.12 found a survival rate of
approximately 70% at 2 years (as compared to 43% in
a historical control). The patients in the current study were
less restricted in terms of cardiac output and NYHA class.
Thus, any direct comparison of these studies should be
undertaken with great caution.
In a separate analysis, event-free survival (defined as
absence of death, lung transplantation, or initiation of
alternative targeted PAH therapy) during the 2-year study
period in patients with IPAH was calculated at 74% (95% CI,
60e88%). Two previous studies found that first-line bosen-
tan therapy was associated with event-free survival rates of
55%26 and 45%25 at 2 years, but again, these studies cannot
be directly compared with the current study, because the
availability of intravenous prostanoids as add-on therapy
may have been different, and different definitions were
used for the term ‘event-free survival’. McLaughlin et al.
defined ‘event-free survival’ as the percentage of the
initial cohort who remained alive and on bosentan mono-
therapy,26 and Provencher et al. defined it as survival
without transplantation, prostanoid initiation, or hospital-
ization for right heart failure.25
Examination of PHother patients suggests a less favor-
able prognosis in terms of both overall survival and event-
free survival than in IPAH patients. This may be due to the
fact that PHother patients had a lower mean 6-MWD than
IPAH patients (281 m 139 vs. 376 m 112, respectively) at
entry. In addition, the included diseases may have a less
favorable prognosis, as recently reported for collagen
vascular disease-associated PAH compared with IPAH.31
In a German survey of patients who were started with
a first-line compassionate treatment with inhaled ilo-
prost,32 only 29% of the initial cohort were on monotherapy
with inhaled iloprost after 2 years. This is about half the
number in this study. This may be due to a variety of factors
Long-term inhaled iloprost for PH 739including baseline characteristics, low inhaled doses of
iloprost, reimbursement issues, and emergence of new
treatment options during the observation period. A
controlled German study with a 3-month open-label ilo-
prost treatment in patients on bosentan could not be
interpreted due to low statistical power.33
In conclusion, our results are in accordance with the
findings of previous, shorter-term studies and lend further
support to accruing data indicating the long-term safety
and beneficial clinical effects of inhaled iloprost therapy in
patients with PAH.
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